Nanosonics Limited
3.04
AUD
+0.01
(+0.33%)
ISIN
AU000000NAN9
Return %
Stock
S&P 500
1Y
-32.29
14.20
3Y
-20.83
81.12
5Y
-47.59
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Michael Kavanagh
- Full Time Employees
- 508
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Building A Sydney NSW Australia 2113
- IPO Date
- Apr 16, 2007
- Website
- nanosonics.com.au
- Similar Companies
- Business
- Nanosonics Limited is an Australian infection prevention company specializing in the research, development, manufacturing, and commercialization of innovative automated disinfection technologies primarily for ultrasound probes. Its core product portfolio includes the trophon range of ultrasound probe disinfectors—trophon3, trophon2 Plus, and Trophon EPR—featuring patented sonicated mist technology that enables high-level disinfection (HLD) of both endocavitary and surface ultrasound probes. The company also offers related consumables, accessories, and software solutions such as AuditPro, a workflow compliance management system, and digital connectivity services that enhance traceability and integration with healthcare providers' enterprise systems. Additionally, Nanosonics has developed the CORIS instrument reprocessing platform, targeting high-volume endoscopic procedure markets. Founded in 2000 and headquartered in Macquarie Park, Australia, Nanosonics operates globally across Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific, with over 300 employees. The company targets healthcare facilities including hospitals and private physician offices, focusing on reducing healthcare-acquired infections (HAIs) through its automated disinfection systems. Recent major developments in 2024 and 2025 include the launch of trophon3, a faster and more connected generation of its ultrasound probe disinfector, and the trophon2 Plus software upgrade package, expanding digital traceability and workflow enhancements. Nanosonics also achieved FDA De Novo clearance for its CORIS system and anticipates a phased commercial rollout starting in fiscal 2026, aiming to capitalize on the large addressable market of endoscopic procedures globally. Operationally, the company expanded manufacturing capacity including consumables production in the USA, enhanced service infrastructure, and implemented a new ERP system while strengthening cybersecurity with ISO 27001 re-certification. Nanosonics has also deepened strategic relationships, such as its ongoing collaboration with GE Healthcare, and continues to grow its installed base internationally, particularly targeting growth in developing markets across Europe, the Middle East, and Japan. Through sustained innovation and geographical expansion, Nanosonics positions itself as a global leader in infection prevention technology for ultrasound and other medical device disinfection.
Company News
Nanosonics Limited (NNCSF) Q4 2026 Earnings Call Transcript
Nanosonics Limited (NNCSF) Q2 2026 Earnings Call Transcript
Nanosonics (OTCMKTS:NNCSF) Shares Down 7.8% – Here’s What Happened
Nanosonics Limited (NNCSF) Shareholder/Analyst Call Transcript
Nanosonics Limited (NNCSF) Q4 2025 Earnings Call Transcript
Nanosonics Limited (NNCSF) Q2 2025 Earnings Call Transcript
Nanosonics Limited (NNCSF) Q4 2023 Earnings Call Transcript
Nanosonics Limited (NNCSF) Q2 2023 Earnings Call Transcript